Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs

Abstract EN

Purpose.

To survey the management of patients with neovascular age-related macular degeneration (nvAMD) in Spain.

Methods.

An observational retrospective multicenter study was conducted.

The variables analyzed were sociodemographic characteristics, foveal and macular thickness, visual acuity (VA), type of treatment, number of injections, and the initial administration of a loading dose of an antiangiogenic drug.

Results.

208 patients were followed up during 23.4 months in average.

During the first and second years, patients received a mean of 4.5±1.8 and 1.6±2.1 injections of antiangiogenic drugs, and 5.4±2.8 and 3.6±2.2 follow-up visits were performed, respectively.

The highest improvement in VA was observed at 3 months of follow-up, followed by a decrease in the response that stabilized above baseline values until the end of the study.

Patients who received an initial loading dose presented greater VA gains than those without.

Conclusions.

Our results suggest the need for a more standardized approach in the management and diagnosis of nvAMD receiving VEGF inhibitors.

To achieve the visual outcomes reported in pivotal trials, an early diagnosis, proactive approach (more treating than follow-up visits), and a close monitoring might be the key to successfully manage nvAMD.